Evidence map›Paper›PMID 33119663›Full record

ArticlePloS one2020

Antiretroviral drug use and HIV drug resistance in female sex workers in Tanzania and the Dominican Republic.

Wendy Grant-McAuley, Jessica M Fogel, Noya Galai, William Clarke, Autumn Breaud, Mark A Marzinke, Jessie Mbwambo, Samuel Likindikoki, Said Aboud, Yeycy Donastorg and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Evaluating Barriers to Viral Suppression among People with HIV in Santiago, Dominican Republic.Journal of the International Association of Providers of AIDS Care
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 4 countries.

Wendy Grant-McAuleyDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Jessica M FogelDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Noya GalaiDepartment of Epidemiology, Johns Hopkins University School of Public Health, Baltimore, Maryland, United States of America.
William ClarkeDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Autumn BreaudDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Mark A MarzinkeDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Jessie MbwamboDepartment of Psychiatry, Muhimibili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Samuel LikindikokiDepartment of Psychiatry, Muhimibili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Said AboudDepartment of Microbiology and Immunology, Muhimibili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Yeycy DonastorgUnidad de Investigacion de Vacunas, Instituto Dermatologico y Cirugia de la Piel, Santo Domingo, Dominican Republic.
Martha PerezUnidad de Investigacion de Vacunas, Instituto Dermatologico y Cirugia de la Piel, Santo Domingo, Dominican Republic.
Clare BarringtonDepartment of Health Behavior, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Wendy DavisCenter on Health, Risk and Society, American University, Washington, District of Columbia, United States of America.
Deanna KerriganCenter on Health, Risk and Society, American University, Washington, District of Columbia, United States of America.
Susan H EshlemanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.ORCID 0000-0002-4587-791X
Johns Hopkins University · USMuhimbili University of Health and Allied Sciences · TZAmerican University · USInstituto Dermatológico y Cirugía de Piel "Dr. Huberto Bogaert Díaz" · DOUniversity of North Carolina at Chapel Hill · US

Funding

LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Research Services CoreP2CHD050924 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KAREN B GUZZO · 2015 to 2026
$9.6M
Stigma, Cohesion and HIV Outcomes Among Vulnerable Women Across Epidemic SettingsR01MH110158 · NIMH · JOHNS HOPKINS UNIVERSITY · PI KERRIGAN, DEANNA L · 2016 to 2020
$3.6M
NIAID NIH HHS P30 AI094189NIAID NIH HHS UM1 AI068613NICHD NIH HHS P2C HD050924NIMH NIH HHS R01 MH110158
6 · The paper itself

Abstract

objectiveFemale sex workers (FSW) have increased risk of HIV infection. Antiretroviral treatment (ART) can improve HIV outcomes and prevent HIV transmission. We analyzed antiretroviral (ARV) drug use and HIV drug resistance among HIV-positive FSW in the Dominican Republic and Tanzania.

methodsPlasma samples collected at study entry with viral loads >1,000 copies/mL were tested for ARV drugs and HIV drug resistance. ARV drug testing was performed using a qualitative assay that detects 22 ARV drugs in five classes. HIV genotyping was performed using the ViroSeq HIV-1 Genotyping System. Phylogenetic analyses were performed to determine HIV subtype and assess transmission clusters.

resultsAmong 410 FSW, 144 (35.1%) had viral loads >1,000 copies/mL (DR: n = 50; Tanzania: n = 94). ARV drugs were detected in 36 (25.0%) of 144 samples. HIV genotyping results were obtained for 138 (95.8%) cases. No transmission clusters were observed in either country. HIV drug resistance was detected in 54 (39.1%) of 138 samples (31/35 [88.6%] with drugs detected; 23/103 [22.3%] without drugs detected); 29/138 (21.0%) had multi-class resistance (MCR). None with MCR had integrase strand transfer inhibitor resistance. In eight cases, one or more ARV drug was detected without corresponding resistance mutations; those women were at risk of acquiring additional drug resistance. Using multivariate logistic regression, resistance was associated with ARV drug detection (p<0.001), self-reported ART (full adherence [p = 0.034]; partial adherence [p<0.001]), and duration of HIV infection (p = 0.013).

conclusionsIn this cohort, many women were on ART, but were not virally suppressed. High levels of HIV drug resistance, including MCR, were observed. Resistance was associated with detection of ARV drugs, self-report of ART with full or partial adherence, and duration of HIV infection. These findings highlight the need for better HIV care among FSW to improve their health, reduce HIV drug resistance, and decrease risk of transmission to others.

Indexed as

AdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCohort StudiesDominican RepublicDrug Resistance, ViralFemaleGenotypeHIV-1HIV InfectionsHumansPhylogenySex WorkersTanzaniaViral LoadYoung AdultAnti-HIV Agents

Identifiers

PMID33119663
PMCPMC7595323
OpenAlexW3096923078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.